Previous 10 | Next 10 |
2024-01-23 17:13:36 ET More on Ensysce Biosciences ELAB, KIND and RLX among pre-market losers Seeking Alpha’s Quant Rating on Ensysce Biosciences Historical earnings data for Ensysce Biosciences Financial information for Ensysce Biosciences R...
2024-01-23 16:38:48 ET We try not to continually focus on a specific industry or sector over and over again, but sometimes a particular industry is just on fire. That’s what we’ve been seeing in the %Biotech space over the last few months, and it doesn’t seem like i...
2024-01-23 09:59:59 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
~ FDA acknowledges significant potential impact of MPAR's oral overdose protection ~ SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug s...
2024-01-17 09:00:32 ET Losers: DatChat DATS -32% plans to sell shares through public offering . Acurx Pharmaceuticals ( NASDAQ: ACXP ) -24% announces positive comparative Microbiology and Microbiome data for Ibezapolstat from phase 2b clinical trial in CDI ...
2024-01-17 08:46:36 ET More on pre-market gainers Impinj: Secular Tailwinds Provide Long Runway But Short-Term Headwinds Persist Sinclair Continues To Face Challenges Solid Power: Too Risky For Me Sinclair announces global settlement of all Diamond Sports Gro...
2024-01-17 08:36:18 ET More on Ensysce Biosciences Ensysce Biosciences gets $1.7M note financing For further details see: Ensysce Biosciences files to sell common stock, warrants
SAN DIEGO, CA / ACCESSWIRE / January 8, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Ki...
2023-12-20 08:36:29 ET Losers: Bluebird bio BLUE -52% on pricing of $125 million stock offering . Jin Medical International Ltd ( ZJYL ) -14% . Argen X SE ( ARGX ) -25% reports topline results from address study of Efgartigimod SC in Pemphigus . ...
SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to ...
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmac...
~ Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~ SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative...